UNSPSC 51162646: Pentoxyverine

This classification denotes a cyclopentane and antitussive agent with the molecular formula C20H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 32C726X12W, chemically known as 2-(2-diethylaminoethoxy)ethyl 1-phenylcyclopentane-1-carboxylate; 2-hydroxypropane-1,2,3-tricarboxylic acid but more generally known as pentoxyverine, which bears US NIH Compound Identifier 2562. European Medicines Agency schedules Pentoxyverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09706MIG.

UNSPSC 51162646 Pentoxyverine is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent activity under this specific code focuses more broadly on naloxone, drug deactivation systems, and generic multi-source pharmaceuticals. State and local governments buying under this code include county health departments and departments of administration overseeing cooperative purchasing alliances. Seminole County, Florida and the Minnesota Department of Administration (through the Minnesota Multistate Cooperative Purchasing Alliance) represent recent active buyers. The actual procurement scope extends beyond the code's nominal product name to encompass emergency response pharmaceuticals, over-the-counter products, and related health-support systems distributed through authorized wholesalers and direct county procurement channels.

Recent opportunities show activity concentrated in Florida and Minnesota. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida, with a response deadline of July 26, 2026. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 through MMCAP on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across Minnesota and Oregon, with proposals due March 26, 2026. MMCAP contracts leverage three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and require vendors to maintain cGMP certification and Drug Supply Chain Security Act compliance. Both procurements emphasize electronic submission, product compliance documentation, and fixed pricing or net-price formats; neither identified explicit set-aside designations for disadvantaged enterprises in the available materials.